IBD Flare-Ups Predicted Before They Even Start

FEATURED RESEARCH

IBD Flare-Ups Predicted Before They Even Start

Managing inflammatory bowel disease (IBD), which affects more than 6 million people worldwide, is a major challenge.

Both Crohn’s disease and ulcerative colitis are chronic conditions that cause inflammation in the digestive tract, often resulting in symptoms like severe abdominal pain, diarrhea, and fatigue.

Despite advancements in treatment, around 30% of patients do not respond to conventional therapies, making long-term remission difficult to achieve.

What’s the big change? Researchers at the First Hospital of Jilin University, along with teams from University College Cork, have integrated AI with advanced endoscopic techniques like Olympus endocytoscopy and virtual chromoendoscopy.

These tools are incredibly accurate—offering up to 96% sensitivity in detecting histological remission. This helps doctors get a real-time, detailed look inside the gut, spotting even the tiniest signs of inflammation.

Why should you care? Traditional methods sometimes miss subtle inflammation, but AI-driven systems now offer up to 90% accuracy in predicting clinical relapse.

This precision helps doctors tailor treatments for long-term remission, rather than just reacting to symptoms.

AI is also transforming digital pathology, enabling more detailed analysis of tissue samples and improving the identification of disease markers.

Looks like AI is about to 'gut' your IBD worries before they even start!

For more details: Full Article

Brain Booster

Select the right answer! (See explanation below)

Funds Raised

GPCR DRUG DISCOVERY

Superluminal Medicines Secures $120 Million to Supercharge Drug Discovery

Superluminal Medicines just closed a $120 million Series A funding round led by RA Capital Management.

The round included major players like Insight Partners, Eli Lilly, and NVIDIA's NVentures.

This significant boost will push Superluminal's lead programs into clinical development and expand their small molecule drug pipeline, especially focusing on the highly valuable GPCR targets.

Why it matters: GPCRs (G protein-coupled receptors) play a massive role in cell signaling, and about 35% of all approved drugs target them. Yet, 70% of over 800 GPCRs are still unexplored.

Superluminal’s platform combines generative biology, chemistry, and machine learning to quickly create drug candidates.

The company’s goal is to revolutionize how we discover medicines, making it faster and more precise.

The science behind it: Superluminal’s platform explores the dynamic nature of proteins, targeting precise structural changes to identify disease states.

Their discovery engine, fueled by advanced in silico prediction models, enables them to design highly selective compounds quickly and efficiently.

What’s next? With six small molecule programs already in motion, this funding round ensures Superluminal can continue to build out its pipeline and bring game-changing treatments to market faster.

The future of drug discovery might just be arriving at light speed!

For more details: Full Press Release

💰 7 Other funded companies

1. Inflammatix raised $57 million to commercialize its AI-powered TriVerity test, which detects infections and assesses sepsis risk, as it awaits FDA review. [Link]

2. SpectraWAVE raised $50 million to enhance its AI-powered HyperVue coronary imaging system, which helps analyze artery blockages and guide stent placement, following two FDA clearances in 2023. [Link]

3. Pieces Technologies raised $25 million to expand its AI-driven clinical solutions, which automate documentation tasks like progress notes and discharge planning, freeing up time for healthcare providers. [Link]

4. Viome raised $25 million in a Series D round to expand its diagnostics division, using its AI-driven platform to develop early detection models for cancer and chronic diseases, while appointing former Amazon executive Kal Raman as COO. [Link]

5. ArcanaBio secured funding from BioInnovation Institute to advance its AI-powered diagnostic technologies, focusing on nano-photonics and biosensors for at-home, lab-grade testing. [Link]

6. Somite.ai raised an additional $4.8 million, bringing its pre-seed total to $10 million, to advance its AI-driven cell replacement therapies and further develop its AlphaStem platform. [Link]

7. PathPresenter raised $7.5 million in Series A funding, led by AVANT BIO, to accelerate adoption of its AI-powered, vendor-agnostic digital pathology platform used by top medical institutions for clinical care, education, and research. [Link]

New Partnerships

DRUG DISCOVERY

Gilead and Genesis Join Forces to Fast-Track Drug Discovery with AI

Gilead Sciences and Genesis Therapeutics have teamed up in a strategic collaboration to develop novel small-molecule therapies for hard-to-treat diseases.

The partnership leverages Genesis' cutting-edge AI platform, GEMS (Genesis Exploration of Molecular Space), designed to generate and optimize drug candidates against complex protein targets.

The power of AI in drug discovery: Genesis Therapeutics is at the forefront of using generative AI for drug discovery.

Their GEMS platform uses advanced machine learning, diffusion models, and physical simulations to tackle challenging targets.

With Gilead’s experience in clinical development, the partnership aims to push these AI-generated molecules into trials and, eventually, the market.

Financial breakdown: Genesis will receive a $35 million upfront payment, with the potential to earn additional milestones and royalties based on the success of these programs.

Gilead will have exclusive rights to commercialize any therapies developed from the collaboration.

Looking ahead: Gilead and Genesis are targeting unmet patient needs by creating therapies for difficult protein targets.

This collaboration shows the increasing importance of AI in accelerating the drug development process and could lead to major breakthroughs in treating complex diseases.

For more details: Full Press Release

🤝 4 Other collaborations shaping the future

1. AvaSure, Oracle, and NVIDIA partnered to create an AI-powered virtual concierge for hospitals, designed to streamline workflows, assist with staffing and patient requests, and improve care efficiency, with availability expected next year. [Link]

2. Fimlab partnered with Proscia to deploy its AI-enabled digital pathology platform, enhancing Fimlab's diagnostic capabilities with more precise, efficient image analysis and AI-driven workflows for improved patient outcomes. [Link]

3. RapidAI partnered with the Alaska Stroke Coalition to launch "Rapid AK," deploying AI-powered stroke care solutions to help rural hospitals improve diagnosis and treatment, addressing the state's unique healthcare challenges. [Link]

4. Firefly Neuroscience partnered with Zeto to integrate its AI-driven Brain Network Analytics (BNA™) technology with Zeto’s FDA-cleared EEG platform, enhancing brain health diagnostics for neurological conditions and expanding accessibility to healthcare providers. [Link]

Milestone Moments

⚡5 Product launches

1. Salesforce unveiled new AI tools for healthcare, including patient matching for clinical trials and automated health assessments, with full rollout by early 2025. [Link]

2. Innovaccer launched its AI-powered Care Management Copilot, featuring its AI model Sara, to automate documentation tasks, saving care managers over 10 hours per week and enabling 30-40% more patient engagement. [Link]

3. WhiteGlove, an AI-enabled healthcare concierge, launched to help U.S.-based individuals manage medical care for family in India, offering services like digitized health records, appointment coordination, and real-time updates for long-term, preventative care. [Link]

4. Roche expanded its digital pathology platform by integrating over 20 AI algorithms from eight collaborators, enhancing cancer diagnostics and precision medicine through its navify Digital Pathology software. [Link]

5. Theora Care launched AI-driven Smart Fall Detection™ with 95% accuracy, integrated into its Theora Connect wearable to enhance safety for older adults and ease caregiver concerns. [Link]

Opinion and Perspectives

AI IN HEALTHCARE

Insurers Are Using AI to Deny Your Healthcare – And It’s Getting Worse

Hospitals are grappling with growing administrative costs, now making up over 40% of expenses, driven in part by increasing claims denials.

From 2022 to 2023, denials surged by 20.2% for commercial plans and 55.7% for Medicare Advantage, largely due to insurers using AI tools, according to the American Hospital Association (AHA).

The issue? AI algorithms are being used to process claims, but they often deny care without considering individual clinical details.

The AHA warns this can lead to automatic denials without proper human review.

CMS raises concerns: While Medicare Advantage’s 2024 rule offered guidance, the Centers for Medicare & Medicaid Services (CMS) cautioned that AI could perpetuate discrimination and bias.

Insurers are urged to ensure these tools don’t introduce or reinforce biases.

Lawsuits loom: Insurers like UnitedHealthcare, Humana, and Cigna face lawsuits over AI-driven wrongful care denials.

CMS stressed that while AI can support decisions, it cannot be used alone to deny coverage without human oversight.

For more details: Full Article

We Value Your Thoughts!

Trivia Answer: C) They are expelled by the worker bees and left to die.

Once the mating season wraps up, the drones are pretty much done with their one job. So, the worker bees kick them out to save food for the winter. Drones can’t fend for themselves, so they end up outside the hive where—sorry, boys—they don’t make it. Think of it like being evicted after a summer party with no backup plan!

Stay Ahead in AI Healthcare!

Get the no-spam free weekly update of the latest news on startups, new partnerships, and acquisitions.

Read deep dives on emerging technologies, market analysis, and fascinating AI biotech research!

See you next week,
Bauris